William J. Gradishar, MD, discusses the current treatment landscape in metastatic HER2-positive breast cancer.
William J. Gradishar, MD, chief of hematology and oncology, Department of Medicine; Betsy Bramsen Professorship of Breast Oncology; and a professor of medicine (hematology and oncology) at Northwestern University Feinberg School of Medicine, discusses the current treatment landscape in metastatic HER2-positive breast cancer.
In the past year, a number of regulatory approvals have expanded the HER2-positive breast cancer armamentarium, Gradishar says. Moreover, several other agents are poised to enter the space.
Two of the most recent approvals were of the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (Enhertu) and the selective HER2-directed TKI tucatinib (Tukysa), the latter of which was evaluated in the phase 2 HER2CLIMB trial, says Gradishar.
Both agents have demonstrated significant clinical activity and unique strengths, Gradishar explains. However, patients may experience some toxicities with either regimen.
Furthermore, neratinib (Nerlynx) was initially approved as an adjuvant therapy in HER2-positive breast cancer. However, after the results of the phase 3 NALA trial read out, the TKI received an indication in the metastatic setting after progression on at least 2 anti–HER2-based regimens, Gradishar concludes.